Clinical Trials in Orbassano, Torino
18 recruiting
Showing 1–17 of 17 trials
Recruiting
Phase 1Phase 2
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
MetastasisCastration-Resistant Prostatic Cancer
Merck Sharp & Dohme LLC360 enrolled78 locationsNCT06863272
Recruiting
Phase 2Phase 3
A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Metastatic Non-small Cell Lung Cancer With MTAP Deletion
Bristol-Myers Squibb590 enrolled277 locationsNCT07063745
Recruiting
Phase 3
The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
Sickle Cell Disease
Sanofi192 enrolled54 locationsNCT06975865
Recruiting
Scaffold in Emilia Romagna and in the MAGIC Network
Coronary Artery Disease
University Hospital of Ferrara1,111 enrolled17 locationsNCT03327961
Recruiting
Phase 3
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
Sickle Cell Disease
Novo Nordisk A/S408 enrolled172 locationsNCT06612268
Recruiting
Phase 3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Solid TumorsHematologic Malignancies
Merck Sharp & Dohme LLC3,500 enrolled779 locationsNCT03486873
Recruiting
Phase 3
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
Multiple Sclerosis
Sanofi1,600 enrolled384 locationsNCT06141473
Recruiting
Phase 3
A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
Lung CancerEGFRNSCLC, Stage IB-IIIA+5 more
Taiho Oncology, Inc.360 enrolled253 locationsNCT07128199
Recruiting
Phase 3
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
Patients With Non-small-cell Lung Cancer
OSE Immunotherapeutics363 enrolled207 locationsNCT06472245
Recruiting
The Epithelioid Hemangioendothelioma Registry of the European Reference Network on Rare Adult Solid Cancers (EURACAN)
Sarcoma,Soft TissueEpithelioid Hemangioendothelioma
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano100 enrolled22 locationsNCT06408441
Recruiting
Phase 2
Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma
Soft Tissue SarcomaLeiomyosarcoma of Ovary
Italian Sarcoma Group100 enrolled17 locationsNCT04383119
Recruiting
Phase 3
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
Sickle Cell DiseaseThalassemia
Novo Nordisk A/S480 enrolled103 locationsNCT06609226
Recruiting
Phase 2
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
MyelofibrosisModerate ThrombocytopeniaMild Thrombocytopenia
Karyopharm Therapeutics Inc58 enrolled70 locationsNCT05980806
Recruiting
Prospective Observational Study of Localized Angiosarcoma of Any Site: ProStars
Angiosarcoma
Italian Sarcoma Group250 enrolled19 locationsNCT06375941
Recruiting
ALFAOMEGA Master Observational Trial
Colorectal, Cancer
IFOM ETS - The AIRC Institute of Molecular Oncology3,000 enrolled19 locationsNCT04120935
Recruiting
PRostate Cancer Plasma Integrative Multi-modal Evaluation
Metastatic Prostate Cancer
Santa Chiara Hospital800 enrolled4 locationsNCT06981377
Recruiting
Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients
Prostate CancerMetastatic TumorHormone Sensitive Prostate Cancer
Santa Chiara Hospital3,000 enrolled3 locationsNCT06473259